NCT06086886View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986454 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

November 16, 2023

Primary Completion Date

December 20, 2024

Study Completion Date

December 20, 2024

Conditions
Healthy Participants
Interventions
DRUG

BMS-986454

Specified dose on specified days

OTHER

Placebo

Specified dose on specified days

Trial Locations (2)

NW10 7EW

Local Institution - 0002, London

NG11 6JS

Local Institution - 0001, Nottingham

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06086886 - A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986454 in Healthy Participants | Biotech Hunter | Biotech Hunter